Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Aardvark Adventures -- Ignore unavailable to you. Want to Upgrade?

To: ~digs who wrote (2894)	1/23/2008 12:07:32 AM
From: ~digs	Respond to of 7944

[VVUS] VIVUS INC > 6.18 +0.19 ( +3.17%) Open > 5.85 Volume > 602883 VIVUS, Inc., a pharmaceutical company, engages in the development and commercialization of therapeutic products to treat obesity, post-menopausal, and sexual health in women and men in the United States. Its investigational product pipeline includes Qnexa, which has completed a Phase II clinical trial for treating obesity; Testosterone MDTS that has completed Phase II study to treat hypoactive sexual desire disorder; Avanafil, which has completed Phase II clinical trial for the treatment of erectile dysfunction; and ALISTA that has completed Phase IIb study for the treatment of female sexual arousal disorder. The company also markets MUSE for the treatment of erectile dysfunction.